Xofigo (Radium 223) is a medication that we deliver in the office for men with metastatic prostate cancer that has become resistant to testosterone lowering medications ("castration-resistant") who have painful bone metastases. This therapy is well-tolerated and extends survival by 3-7 months, reduces bone pain and the risk of developing a bone fracture. Watch this short video to see how it's done.
Dr. Lawenda Discusses Xofigo (Radium-223) for Metastatic Castration Resistant Prostate Cancer
Xofigo (Radium 223) is a medication that we deliver in the office for men with metastatic prostate cancer that has become resistant to testosterone lowering medications ("castration-resistant") who have painful bone metastases. This therapy is well-tolerated and extends survival by 3-7 months, reduces bone pain and the risk of developing a bone fracture. Watch this short video to see how it's done.
0 Comments